In evaluating a controversial new therapy, which considerations are essential?

In evaluating a controversial new therapy, which considerations are essential?

• A. Only the costs of treatment
• B. Costs versus benefits and robustness of evidence, including unpublished data
• C. Public opinion is the sole factor
• D. Approving based on marketing materials

Answer: (B)

When evaluating a controversial therapy, the essential approach is to weigh costs and benefits while judging how strong the supporting evidence is, including data that may not be published. This combination helps avoid adopting treatments that are ineffective or unsafe simply because they seem appealing financially or politically, and it also prevents discarding potentially beneficial options due to isolated or incomplete data. Relying only on costs misses crucial information about effectiveness and safety. Public opinion is not a reliable guide for patient welfare or resource use, and marketing materials are designed to persuade rather than to provide objective, comprehensive evidence. By integrating economic considerations with a critical appraisal of robust data—recognizing that unpublished results can reveal biases or missing risks—you make a more responsible, patient-centered decision.

When evaluating a controversial therapy, the essential approach is to weigh costs and benefits while judging how strong the supporting evidence is, including data that may not be published. This combination helps avoid adopting treatments that are ineffective or unsafe simply because they seem appealing financially or politically, and it also prevents discarding potentially beneficial options due to isolated or incomplete data.

Relying only on costs misses crucial information about effectiveness and safety. Public opinion is not a reliable guide for patient welfare or resource use, and marketing materials are designed to persuade rather than to provide objective, comprehensive evidence. By integrating economic considerations with a critical appraisal of robust data—recognizing that unpublished results can reveal biases or missing risks—you make a more responsible, patient-centered decision.